Targets to retard the progression of diabetic nephropathy

Slides:

Advertisements

Similar presentations

Steven Fishbane, Jeffrey S. Berns, M.D. Kidney International

Advertisements

Volume 55, Issue 2, Pages (February 1999)

Iron status and iron supplementation in peritoneal dialysis patients

Anemia management in chronic kidney disease

Mitchell H. Rosner, W. Kline Bolton Kidney International

Volume 83, Issue 3, Pages (March 2013)

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Blaithin A. McMahon, Patrick Thomas Murray Kidney International

From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria Paul E. De Jong, Barry M. Brenner Kidney International

ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target Szu-Chun Hung, Der-Cherng Tarng Kidney International

Volume 67, Issue 6, Pages (June 2005)

Volume 76, Issue 5, Pages (September 2009)

Volume 56, Pages S31-S36 (July 1999)

Prehypertension and chronic kidney disease: the ox or the plow?

Volume 80, Issue 10, Pages (November 2011)

Progression of renal failure and hypertensive nephrosclerosis

Peter Rossing, Philip Hougaard, Hans-Henrik Parving

Mortality caused by sepsis in patients with end-stage renal disease compared with the general population Mark J. Sarnak, Bertrand L. Jaber Kidney International

John P. Middleton, Patrick H. Pun Kidney International

‘Progressive diabetic nephropathy. How useful is microalbuminuria

Volume 66, Issue 3, Pages (September 2004)

Yasuhiro Hamada, Masafumi Fukagawa Kidney International

Volume 77, Issue 9, Pages (May 2010)

Volume 77, Issue 8, Pages (April 2010)

Volume 55, Issue 2, Pages (February 1999)

Volume 77, Issue 1, Pages 5-6 (January 2010)

Comorbidity and confounding in end-stage renal disease

D. Batlle, P. Ramadugu, M.J. Soler Kidney International

Joseph W. Eschbach, John W. Adamson Kidney International

Volume 70, Issue 3, Pages (August 2006)

Manjula Kurella Tamura, Kristine Yaffe Kidney International

Volume 73, Issue 7, Pages (April 2008)

Renal risk scores: Progress and prospects

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

The role of protein kinase C activation in diabetic nephropathy

Erythropoietin and progression of CKD

Volume 70, Issue 8, Pages (October 2006)

Volume 70, Issue 7, Pages (October 2006)

Volume 74, Issue 6, Pages (September 2008)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Tilman B. Drüeke, Ziad A. Massy Kidney International

Volume 63, Pages S38-S42 (February 2003)

Linda F. Fried, Trevor J. Orchard, Bertram L. Kasiske

Volume 65, Issue 4, Pages (April 2004)

Volume 79, Issue 3, Pages (February 2011)

Methods for guideline development

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Volume 67, Issue 4, Pages (April 2005)

Volume 66, Issue 3, Pages (September 2004)

Volume 62, Issue 6, Pages (December 2002)

Tatsumi Moriya, Thomas J. Groppoli, Youngki Kim, Michael Mauer

Volume 60, Issue 1, Pages (July 2001)

Volume 80, Issue 3, Pages (August 2011)

Fibrosis and renal aging

H. Raffi, J.M. Bates, Z. Laszik, S. Kumar Kidney International

Volume 63, Issue 3, Pages (March 2003)

Volume 80, Issue 10, Pages (November 2011)

Is complement a target for therapy in renal disease?

Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular.

Amylin deposition in the kidney of patients with diabetic nephropathy

Volume 56, Issue 4, Pages (October 1999)

H.J. Chin, H. Ro, H.J. Lee, K.Y. Na, D.-W. Chae Kidney International

Volume 55, Issue 3, Pages (March 1999)

Volume 53, Issue 5, Pages (May 1998)

Volume 80, Issue 9, Pages (November 2011)

Volume 57, Issue 2, Pages (October 2000)

Mary B. Leonard, Lynn A. Donaldson, Martin Ho, Denis F. Geary

The Ebf1 knockout mouse and glomerular maturation

Acute phosphate nephropathy

Presentation transcript:

Targets to retard the progression of diabetic nephropathy Mark E. Cooper, Karin Jandeleit-Dahm, Merlin C. Thomas Kidney International Volume 68, Issue 4, Pages 1439-1445 (October 2005) DOI: 10.1111/j.1523-1755.2005.00555.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Glomerular hypertrophy and mesangial expansion in diabetic c57 and diabetic apolipoprotein E knockout mice. (A) c57. (B) Diabetic c57. (C) Apolipoprotein E knockout control. (D) Diabetic apolipoprotein E knockout [periodic acid-Schiff (PAS) staining ×400]. Kidney International 2005 68, 1439-1445DOI: (10.1111/j.1523-1755.2005.00555.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 The prevalence of functional erythropoietin (EPO) deficiency (<31 IU/mL) and reduced iron availability [transferrin saturation (TSAT) <16%] in patients with type 2 diabetes and anemia, stratified according to the renal function. GFR is glomerular filtration rate. Kidney International 2005 68, 1439-1445DOI: (10.1111/j.1523-1755.2005.00555.x) Copyright © 2005 International Society of Nephrology Terms and Conditions